(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 34.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.53%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.5%.
Ardelyx's revenue in 2026 is $407,320,000.On average, 14 Wall Street analysts forecast ARDX's revenue for 2026 to be $138,071,848,927, with the lowest ARDX revenue forecast at $129,814,368,060, and the highest ARDX revenue forecast at $148,848,020,869. On average, 14 Wall Street analysts forecast ARDX's revenue for 2027 to be $184,813,556,039, with the lowest ARDX revenue forecast at $167,261,197,688, and the highest ARDX revenue forecast at $197,848,456,784.
In 2028, ARDX is forecast to generate $242,902,861,598 in revenue, with the lowest revenue forecast at $213,176,420,971 and the highest revenue forecast at $262,659,994,317.